****

**Routing Sheet – PRMC Expedited Review (Cooperative Studies)**

**Study Title:**

**Principal Investigator:**

***Is this an NCORP study for administrative expedited review ONLY (No patients enrolled at GCC/AU)?***

**☐ Yes ☐ No**

**If yes, please stop here.**

|  |
| --- |
| **For Cooperative studies that will enroll at GCC, please fill out the following information:** |
| **Phase: NA / I / II / III / IV** |
| **Local PI:** |  |
| **Sub-Investigators:**  |  |
| **Study Coordinator:** |  |
| **Length of Accrual Period:** |  | **years** |
| **Total Study Accrual Goal:** |  | **(all sites)** |
| **Local patient pop. meeting criteria:** |  | **(per year)** |
| **Estimated local patient accrual:** |  | **(per year)** |

**Prioritization**

The PI should score this section as described in each category below. Protocols will be rated as **high** or **low** priority based on the Prioritization score and general discussion from the committee.

|  |  |
| --- | --- |
| **Category/Criteria** | **Score** |
| **The study enhances the reputation of the Georgia Cancer Center.** YES=1, NO=0  |  |
| **The study provides care that does not exist at the Institution.** YES=1, NO=0 |  |
| **The study enhances referrals of patients.** YES=1, NO=0 |  |
| **The study contributes to GCC NCORP (NCI Community Oncology Research Program).** YES=1, NO=0 |  |
| **Patient accrual: Expected total number of patients enrolled per trial:**Score 3 = at least 2 patients in Phase I or Phase II trialScore 3 = more than 20 patients in Phase III trialScore 2 = 5 to 19 patients in Phase III or Phase IV trialScore 1 = less than 5 patients in Phase III or Phase IV trial |  |
| **The study provides the only way to access the investigational drugs/ agents.** YES=1, NO=0 |  |
| **Total Score** | **/ 8** |

**Please provide a justification to open the study at GCC/AU (e.g., reason to open, programmatic strategy, good use of available time and monetary resources).**

**Additional Comments:**

**PI Signature: Date:**